Analysis of treatment response in metastatic prostate cancer using circulating tumour cells from longitudinal clinical trials and novel patient-derived organoids in culture

The aims of this project are:

  1. Analyse longitudinal changes in CTCs from the ADMET trial of advanced metastatic prostate cancer patients initiating ADT and randomised to metformin. The CTCs will be expanded ex vivo in organoid culture to investigate intrapatient treatment response and response between treatment arms.

  2. In a subset of ADMET patients from Aim 1, investigate the correlation, relevance and clinical utility of genomic analyses of patient matched CTCs, cfDNA and metastatic tissue biopsies as surrogate measures of metastatic disease, and treatment driven genomic selection.



Colleen Nelson APCRC-Q, IHBI, QUT, TRI
Niall Corcoran APCRC-Epworth
Melanie Lehman APCRC-Q, IHBI, QUT, TRI


2016 - 2016


PA Research Support Scheme  $75 000

Upcoming Events

Jul 19, 2020 - Jul 21, 2020 ANZUP 2020 Annual Scientific Meeting
Adelaide Convention Centre, South Australia
Aug 18, 2020 - Aug 21, 2020 PA Hospital Health Symposium
Russell Strong Auditorium, Princess Alexandra Hospital, 199 Ipswich Rd, Woolloongabba
Aug 21, 2020 - Aug 23, 2020 21st Asia-Pacific Prostate Cancer Conference
Melbourne Convention and Exhibition Centre, Victoria
Sep 29, 2020 - Oct 02, 2020 ComBio 2020
Melbourne Convention and Exhibition Centre, Victoria
Nov 11, 2020 - Nov 13, 2020 COSA Annual Scientific Meeting
Brisbane Convention and Exhibition Centre, Queensland